Keros Therapeutics, Inc.
KROS
$14.41
$0.251.77%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 214.71M | 3.55M | 651.00K | 271.00K | 234.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 214.71M | 3.55M | 651.00K | 271.00K | 234.00K |
| Cost of Revenue | 10.45M | 0.00 | 30.23M | 15.15M | 7.17M |
| Gross Profit | 204.26M | 3.55M | -29.58M | -14.88M | -6.93M |
| SG&A Expenses | 40.94M | 40.75M | 39.19M | 38.52M | 37.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 225.02M | 214.38M | 204.69M | 188.93M | 179.79M |
| Operating Income | -10.31M | -210.83M | -204.03M | -188.66M | -179.56M |
| Income Before Tax | 14.56M | -187.05M | -181.57M | -168.05M | -160.30M |
| Income Tax Expenses | 10.34M | 300.00K | -- | -- | -- |
| Earnings from Continuing Operations | 4.21 | -187.35 | -181.57 | -168.05 | -160.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.21M | -187.35M | -181.57M | -168.05M | -160.30M |
| EBIT | -10.31M | -210.83M | -204.03M | -188.66M | -179.56M |
| EBITDA | -9.01M | -209.60M | -202.89M | -187.62M | -178.63M |
| EPS Basic | -0.14 | -5.01 | -5.21 | -5.13 | -5.14 |
| Normalized Basic EPS | 0.07 | -3.13 | -3.25 | -3.20 | -3.21 |
| EPS Diluted | -1.59 | -6.42 | -6.62 | -6.46 | -6.47 |
| Normalized Diluted EPS | 0.04 | -3.13 | -3.25 | -3.20 | -3.21 |
| Average Basic Shares Outstanding | 154.59M | 149.72M | 139.51M | 131.58M | 125.08M |
| Average Diluted Shares Outstanding | 155.05M | 149.72M | 139.51M | 131.58M | 125.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |